Aytu BioPharma, Inc. (AYTU) |
| 2.24 -0.06 (-2.61%) 08-27 16:00 |
| Open: | 2.3 |
| High: | 2.3387 |
| Low: | 2.23 |
| Volume: | 25,592 |
| Market Cap: | 24(M) |
| PE Ratio: | -1.17 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.46 |
| Resistance 1: | 2.30 |
| Pivot price: | 2.34 |
| Support 1: | 2.03 |
| Support 2: | 1.69 |
| 52w High: | 3.07 |
| 52w Low: | 1.65 |
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
| EPS | -4.610 |
| Book Value | 3.270 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.417 |
| Profit Margin (%) | -60.17 |
| Operating Margin (%) | -32.74 |
| Return on Assets (ttm) | -3.7 |
| Return on Equity (ttm) | -97.4 |
Mon, 24 Aug 2026
AYTU | AYTU BioPharma, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative
Fri, 14 Aug 2026
Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan
Wed, 12 Aug 2026
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility Persists - Risk Parity Rebalance - vinanet.vn
Mon, 20 Jul 2026
New Strong Sell Stocks for July 20th - Eastern Progress
Thu, 16 Jul 2026
New Strong Sell Stocks for July 16th - Yahoo Finance
Thu, 25 Jun 2026
Aytu BioPharma Ends Metadate CD License With Lannett; Sell-Through Allowed After Mutual Termination - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |